Ozempic vs Mounjaro: An Honest Comparison for Weight Loss
Ozempic (semaglutide) vs Mounjaro (tirzepatide) in plain language: how much weight each takes off, side effects, cost, dosing, and how to choose — from someone who has used one and was just prescribed the other.
Mounjaro (tirzepatide) takes off more weight on average in the trials. But for most people the right choice is whichever one you tolerate, can afford, and can actually get hold of — and that is often Ozempic.
Why I'm Writing This
Most "Ozempic vs Mounjaro" articles are written by people who have used neither. I've used one and was just prescribed the other. I ran a tirzepatide (Mounjaro) protocol earlier this year, paused it around surgery, and in June my doctor in Saigon wrote me a prescription for semaglutide (Ozempic) to resume treatment. So I've sat on both sides of this decision — the research, the doctor's reasoning, the cost of actually buying the pen.
This is the plain-language version: how the two drugs differ, what the numbers actually say, and how I'd think about choosing if I were starting over. If you want the same comparison through an endurance-athlete lens — body composition, fueling, power-to-weight — that lives in a separate article.
Same Family, Different Drug
Start with the names, because they cause most of the confusion. Ozempic and Wegovy are the same drug — semaglutide, made by Novo Nordisk. Ozempic is the diabetes label, Wegovy the weight-loss one. Mounjaro and Zepbound are also the same drug — tirzepatide, made by Eli Lilly, with Mounjaro the diabetes label and Zepbound the weight-loss one. Four brand names, two molecules.
The real difference is mechanism. Semaglutide mimics one gut hormone, GLP-1, which your body releases after eating. It tells your brain you're full and slows how fast your stomach empties. Tirzepatide mimics two hormones — GLP-1 and GIP. The second one appears to add to the effect on appetite and how the body handles fat and blood sugar. One target versus two: that's the whole story behind why the trial numbers differ.
How Much Weight Each Takes Off
Here's what the major trials found at the highest approved doses, in people with overweight or obesity:
- Semaglutide (STEP 1 trial): about 15% of body weight lost on average over 68 weeks.
- Tirzepatide (SURMOUNT-1 trial): about 21% of body weight lost on average over 72 weeks at the top dose.
Tirzepatide also beat semaglutide directly in a diabetes study (SURPASS-2), where it produced more weight loss and slightly better blood-sugar control. So on the averages, Mounjaro/Zepbound wins the headline number.
Two honest caveats. First, these are averages — individual results swing widely in both directions, and your diet, sleep, training, and dose all move the needle as much as the molecule does. Second, a higher trial average is worthless if you can't stay on the drug. A medication you quit after two months because of nausea, cost, or supply problems loses to one you take steadily for a year. "Best on paper" and "best for you" are different questions.
Side Effects: Mostly the Same Story
Because both drugs slow your stomach down, they share the same side-effect list: nausea, a sharply reduced appetite, constipation or diarrhea, and sometimes reflux or burping. The symptoms cluster in the first weeks and right after each dose increase, then usually fade as your body adapts.
In the trials, semaglutide tended to report somewhat higher nausea rates than tirzepatide, but the overlap is large and plenty of people find the opposite for themselves. When I started tirzepatide I felt queasy after the first injection and then essentially nothing once I moved the shot to a Friday evening — small timing changes matter more than people expect. The fix is the same for both drugs: go up slowly, eat smaller meals, hydrate, and don't chase a higher dose before the current one feels settled.
The serious-but-rare warnings (pancreatitis, gallbladder issues, a thyroid-tumor signal seen in rodents) apply to both and are the reason these are prescription drugs with a doctor attached, not something to buy and self-manage off a forum protocol.
Dosing and the Slow Ramp
Both are once-weekly injections with a deliberately slow titration so your gut can adjust. My Ozempic prescription is a textbook example: start at 0.25 mg a week, hold for four weeks, step up to 0.5 mg, and only keep climbing (to 1 mg, then 2 mg) if you're tolerating it and haven't reached the goal. Tirzepatide follows the same idea on its own ladder (2.5 mg up through higher doses in monthly steps).
Two practical notes. The starting dose is a tolerance dose, not really a treatment dose — don't judge the drug in week two. And the pens come in specific dose strengths (Ozempic's red starter pen covers 0.25 and 0.5 mg), so know exactly which pen you've been prescribed before you go shopping for it.
Cost and Getting Hold of It
This is where the decision often actually gets made. In the US, both run roughly USD 900–1,200 a month at retail without insurance, and coverage depends on whether you're being treated for diabetes or obesity. Outside the US the picture changes completely.
I'm sourcing in Vietnam, and here the gap is real: a single Ozempic pen is roughly 4.75–5.5 million VND (about USD 185–215), and a hospital pharmacy will usually charge more than a retail chain for the identical pen. Mounjaro, meanwhile, is genuinely hard to find here — several clinics told me it simply isn't stocked — which is part of why my own prescription switched to semaglutide. Availability isn't a footnote; for me it was the deciding factor.
Wherever you buy, two rules: confirm the pen was kept refrigerated (2–8 °C) the whole way, and check the expiry date before you pay. A cheap pen that sat warm is no bargain.
How I'd Actually Choose
If both are available to you and affordable, and your only goal is the most weight off, the trial data points to tirzepatide. That's the simple version. But "both available and affordable" is the part most people don't get to take for granted.
Here's the order I'd run through:
- What can you actually get, reliably? A drug you can refill every month beats one that's out of stock half the year.
- What can you afford to stay on? These work while you take them. Budget for the long haul, not a two-month trial.
- How does it sit with you? If one makes you miserable and the other doesn't, that's your answer regardless of the averages.
- What does your doctor say about your specific health picture? Diabetes, other conditions, and other medications can tip the choice.
Only after those four does "which has the bigger trial number" matter. I ended up on semaglutide not because I think it's the stronger molecule — the data says tirzepatide usually is — but because it's what I can reliably buy and supervise where I live. That's not a compromise; it's the right call for my situation. Yours will turn on your own version of the same questions.
Quick Comparison
| Factor | Ozempic (semaglutide) | Mounjaro (tirzepatide) |
|---|---|---|
| Drug | Semaglutide | Tirzepatide |
| Maker | Novo Nordisk | Eli Lilly |
| Weight-loss brand | Wegovy | Zepbound |
| How it works | GLP-1 only | GLP-1 + GIP (dual) |
| Avg. weight loss (top dose, trials) | ~15% | ~21% |
| Injection | Weekly | Weekly |
| Dose ramp | Slow, 4-week steps | Slow, 4-week steps |
| Main side effects | Nausea, low appetite, GI | Nausea, low appetite, GI |
| Time on market | Since 2017 | Since 2022 |
| Availability (varies by country) | Generally wider | Patchier in some markets |
Bottom line: Mounjaro usually wins the weight-loss average; Ozempic usually wins on track record and how easily you can get it. Pick the one you can tolerate, afford, and refill — and let your doctor, not a comparison table, make the final call. For the endurance-athlete version of this decision, see Tirzepatide vs Semaglutide for Athletes.
Frequently Asked Questions
Is Mounjaro better than Ozempic for weight loss?
On average, in clinical trials, tirzepatide (the drug in Mounjaro and Zepbound) produced more weight loss than semaglutide (Ozempic and Wegovy) — roughly 21% versus 15% of body weight at the highest doses, and tirzepatide also won a head-to-head diabetes trial (SURPASS-2). But 'better on average' is not the same as 'better for you.' The medication you tolerate without quitting, can afford month after month, and can actually buy where you live will out-perform the one with marginally better trial numbers that you stop taking. For most people the deciding factors are side effects, cost, and availability — not the trial averages.
Are Ozempic and Mounjaro the same drug?
No. They are in the same family but they are different molecules. Ozempic is semaglutide, which mimics one gut hormone (GLP-1). Mounjaro is tirzepatide, which mimics two (GLP-1 and GIP). Ozempic and Wegovy are both semaglutide from Novo Nordisk; Mounjaro and Zepbound are both tirzepatide from Eli Lilly. The 'Ozempic/Mounjaro' names are the diabetes brands; 'Wegovy/Zepbound' are the same drugs licensed specifically for weight loss.
Do Ozempic and Mounjaro have different side effects?
The side effects are broadly the same — nausea, reduced appetite, constipation or diarrhea, and occasional reflux — because both slow how fast your stomach empties. Nausea is most common during the first weeks and when you step up a dose. In trials, semaglutide tended to report somewhat higher nausea rates than tirzepatide, but individual variation is huge. The standard fix for both is the same: titrate slowly, eat smaller meals, and don't rush to a higher dose before your body has settled.
How much do Ozempic and Mounjaro cost?
It depends entirely on where you are and whether insurance covers it. In the US, retail is roughly USD 900–1,200 a month for either without coverage. In Vietnam, where I'm sourcing, a single Ozempic pen runs about 4.75–5.5 million VND (~USD 185–215) depending on whether you buy from a hospital pharmacy or a retail chain — retail chains are usually cheaper. Mounjaro is harder to find in some markets. Always confirm the medication was kept cold (2–8 °C) and check the expiry date before buying.
Can you switch from Mounjaro to Ozempic?
Yes, with a doctor's guidance — I did exactly that. You don't carry your old dose across; you restart the new medication near the bottom of its titration ladder and ramp up again, which means another short adjustment period. Time a switch for a stretch when a few weeks of reduced appetite and possible nausea won't derail anything important. The reasons to switch are usually practical: availability, cost, or how a drug sits with you — not a small difference in trial averages.
